Humacyte Stock (NASDAQ:HUMA)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$4.42

52W Range

$2.43 - $9.97

50D Avg

$5.40

200D Avg

$5.39

Market Cap

$567.43M

Avg Vol (3M)

$2.99M

Beta

1.47

Div Yield

-

HUMA Company Profile


Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

183

IPO Date

Dec 01, 2020

Website

HUMA Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceSep 21
Reimbursement of certain allowable costs related to grants$200.00K

Fiscal year ends in Dec 23 | Currency in USD

HUMA Financial Summary


Dec 23Dec 22Dec 21
Revenue-$1.56M$1.26M
Operating Income$-100.05M$-84.58M$-81.21M
Net Income$-110.78M$64.22M$37.54M
EBITDA$-92.33M$-160.34M$-136.98M
Basic EPS$-1.07$0.62$0.94
Diluted EPS$-1.07$0.62$0.94

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 09, 24 | 8:12 PM
Q2 24Aug 13, 24 | 2:46 PM
Q1 24May 10, 24 | 12:00 AM

Peer Comparison


TickerCompany
NRIXNurix Therapeutics, Inc.
SEERSeer, Inc.
KALVKalVista Pharmaceuticals, Inc.
VRDNViridian Therapeutics, Inc.
LRMRLarimar Therapeutics, Inc.
IMCRImmunocore Holdings plc
QSIQuantum-Si incorporated
CRNXCrinetics Pharmaceuticals, Inc.
HCWBHCW Biologics Inc.
MNOVMediciNova, Inc.
GPCRStructure Therapeutics Inc.
KURAKura Oncology, Inc.
CYTKCytokinetics, Incorporated
LYRALyra Therapeutics, Inc.
MIRMMirum Pharmaceuticals, Inc.